Published in Hum Mutat on September 01, 2009
Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem (2010) 2.70
The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol (2015) 1.82
Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res (2010) 1.63
FGF signalling: diverse roles during early vertebrate embryogenesis. Development (2010) 1.60
A Hypomorphic Allele in the FGF8 Gene Contributes to Holoprosencephaly and Is Allelic to Gonadotropin-Releasing Hormone Deficiency in Humans. Mol Syndromol (2010) 1.06
FGF signaling pathway in the developing chick lung: expression and inhibition studies. PLoS One (2011) 0.97
FGFs: Neurodevelopment's Jack-of-all-Trades - How Do They Do it? Front Neurosci (2011) 0.95
Protein targets of inflammatory serine proteases and cardiovascular disease. J Inflamm (Lond) (2010) 0.88
Quantification of shape and cell polarity reveals a novel mechanism underlying malformations resulting from related FGF mutations during facial morphogenesis. Hum Mol Genet (2013) 0.86
1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif Tissue Int (2012) 0.84
FGF8 promotes colorectal cancer growth and metastasis by activating YAP1. Oncotarget (2015) 0.83
The prevention of diabetic cardiomyopathy by non-mitogenic acidic fibroblast growth factor is probably mediated by the suppression of oxidative stress and damage. PLoS One (2013) 0.81
Disruption of G-protein γ5 subtype causes embryonic lethality in mice. PLoS One (2014) 0.79
Signaling from fibroblast growth factor receptor 2 in immature hematopoietic cells facilitates donor hematopoiesis after intra-bone marrow-bone marrow transplantation. Stem Cells Dev (2010) 0.78
The cell cycle regulator CCDC6 is a key target of RNA-binding protein EWS. PLoS One (2015) 0.76
Dual Therapeutic Action of a Neutralizing Anti-FGF2 Aptamer in Bone Disease and Bone Cancer Pain. Mol Ther (2016) 0.75
De-novo protein function prediction using DNA binding and RNA binding proteins as a test case. Nat Commun (2016) 0.75
Analysis of the FGF gene family provides insights into aquatic adaptation in cetaceans. Sci Rep (2017) 0.75
Effects of temperature and additives on stability and spectrum of a therapeutic fibroblast growth factor. Daru (2011) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature (1997) 13.77
Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 9.40
Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell (1991) 8.99
Epidemiology of Parkinson's disease. Lancet Neurol (2006) 8.13
Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell (1996) 7.70
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Receptor specificity of the fibroblast growth factor family. J Biol Chem (1996) 7.58
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet (2000) 7.41
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem (2006) 6.50
An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination. Nat Genet (1998) 5.95
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 5.78
Fgf10 is essential for limb and lung formation. Nat Genet (1999) 5.76
Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science (1991) 5.64
A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet (1995) 4.61
Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev (1998) 4.58
Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet (2003) 4.44
An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development (2000) 4.33
Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev (2005) 3.91
Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology (2004) 3.89
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell (1984) 3.61
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int (2001) 3.44
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet (2004) 3.42
Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol (1992) 3.41
The human FGF-5 oncogene encodes a novel protein related to fibroblast growth factors. Mol Cell Biol (1988) 3.40
Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet (2008) 3.27
Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med (1994) 3.16
Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet (2004) 3.13
FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. Biochem Biophys Res Commun (2000) 3.08
Impaired FGF signaling contributes to cleft lip and palate. Proc Natl Acad Sci U S A (2007) 2.94
All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology (2002) 2.81
Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol (1996) 2.80
Palate development. Development (1988) 2.80
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest (2007) 2.79
Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev (2002) 2.75
Disruption of Fgf10/Fgfr2b-coordinated epithelial-mesenchymal interactions causes cleft palate. J Clin Invest (2004) 2.72
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest (2008) 2.69
Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem (2006) 2.68
Fgf8 is required for pharyngeal arch and cardiovascular development in the mouse. Development (2002) 2.59
Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis. Nature (1992) 2.46
FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev (2002) 2.41
Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology (2004) 2.40
Mice homozygous for a targeted disruption of the proto-oncogene int-2 have developmental defects in the tail and inner ear. Development (1993) 2.39
Critical role for the docking-protein FRS2 alpha in FGF receptor-mediated signal transduction pathways. Proc Natl Acad Sci U S A (2001) 2.28
Orofacial clefting: recent insights into a complex trait. Curr Opin Genet Dev (2005) 2.27
Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem (1993) 2.23
Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc Natl Acad Sci U S A (1996) 2.22
Fibroblast growth factor 2 control of vascular tone. Nat Med (1998) 2.21
Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest (2000) 2.18
Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc Natl Acad Sci U S A (2001) 2.17
Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res (2006) 2.16
Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem (2002) 2.12
Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev (2005) 2.10
Absence of intraepidermal glycosyltransferase ppGalNac-T3 expression in familial tumoral calcinosis. Am J Dermatopathol (2005) 2.09
A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. Am J Hum Genet (2002) 2.02
The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem (2003) 1.99
FGFR2b signaling regulates ex vivo submandibular gland epithelial cell proliferation and branching morphogenesis. Development (2005) 1.98
Expression and function of FGF10 in mammalian inner ear development. Dev Dyn (2003) 1.95
A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.93
Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 1.92
Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Neuron (2002) 1.91
Fibroblast growth factor homologous factor 2B: association with Nav1.6 and selective colocalization at nodes of Ranvier of dorsal root axons. J Neurosci (2004) 1.91
Multiplex relative risk and estimation of the number of loci underlying an inherited disease. Am J Hum Genet (2002) 1.89
Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A (2006) 1.87
Heparan sulfate proteoglycans are essential for FGF receptor signaling during Drosophila embryonic development. Development (1999) 1.86
Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem (2003) 1.86
Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. Neuron (2007) 1.84
Characterization of recombinant human fibroblast growth factor (FGF)-10 reveals functional similarities with keratinocyte growth factor (FGF-7). J Biol Chem (1998) 1.82
Requirements for FGF3 and FGF10 during inner ear formation. Development (2003) 1.76
Mutations in different components of FGF signaling in LADD syndrome. Nat Genet (2006) 1.76
The FGF14(F145S) mutation disrupts the interaction of FGF14 with voltage-gated Na+ channels and impairs neuronal excitability. J Neurosci (2007) 1.74
Fibroblast growth factor homologous factor 1B binds to the C terminus of the tetrodotoxin-resistant sodium channel rNav1.9a (NaN). J Biol Chem (2001) 1.71
Transforming gene from human stomach cancers and a noncancerous portion of stomach mucosa. Proc Natl Acad Sci U S A (1986) 1.71
Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet (2004) 1.70
Processing, secretion, and biological properties of a novel growth factor of the fibroblast growth factor family with oncogenic potential. Mol Cell Biol (1988) 1.69
A protein canyon in the FGF-FGF receptor dimer selects from an à la carte menu of heparan sulfate motifs. Curr Opin Struct Biol (2005) 1.69
The lacrimo-auriculo-dento-digital syndrome. J Pediatr (1973) 1.67
Tumoural calcinosis. Br J Radiol (1966) 1.67
FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23. Bone (2007) 1.66
Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice. Mol Cell Biol (2000) 1.65
FGF/FGFR-2(IIIb) signaling is essential for inner ear morphogenesis. J Neurosci (2000) 1.64
Patterning of frontal cortex subdivisions by Fgf17. Proc Natl Acad Sci U S A (2007) 1.63
Mineralized tissue cells are a principal source of FGF23. Bone (2007) 1.61
Signal transduction by fibroblast growth factor receptors. Front Biosci (1999) 1.61
Fibroblast growth factor homologous factors: evolution, structure, and function. Cytokine Growth Factor Rev (2005) 1.61
Expression pattern of the FGF-related proto-oncogene int-2 suggests multiple roles in fetal development. Development (1989) 1.60
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene (2000) 1.57
FGF10 is an inducer and Pax6 a competence factor for lacrimal gland development. Development (2000) 1.57
Sulfotransferases in glycosaminoglycan biosynthesis. Curr Opin Struct Biol (2003) 1.56
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.56
Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res (2007) 1.52
FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem Biophys Res Commun (2000) 1.49
The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull (2007) 1.46
Mutation analysis in the fibroblast growth factor 14 gene: frameshift mutation and polymorphisms in patients with inherited ataxias. Eur J Hum Genet (2005) 1.44
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med (2006) 3.38
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol (2007) 2.73
Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med (2003) 2.54
Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. Cell (2012) 2.54
Histone H2AX-dependent GABA(A) receptor regulation of stem cell proliferation. Nature (2008) 2.24
Gain-of-function mutations in TRPV4 cause autosomal dominant brachyolmia. Nat Genet (2008) 2.24
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant (2009) 2.17
Evaluation of prenatal-onset osteochondrodysplasias by ultrasonography: a retrospective and prospective analysis. Am J Med Genet A (2008) 1.91
Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med (2006) 1.87
Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med (2007) 1.61
Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin. Nat Genet (2008) 1.40
Autosomal recessive HEM/Greenberg skeletal dysplasia is caused by 3 beta-hydroxysterol delta 14-reductase deficiency due to mutations in the lamin B receptor gene. Am J Hum Genet (2003) 1.40
Interaction of fibroblast growth factor and C-natriuretic peptide signaling in regulation of chondrocyte proliferation and extracellular matrix homeostasis. J Cell Sci (2005) 1.40
Medical foods: inborn errors of metabolism and the reimbursement dilemma. Genet Med (2010) 1.38
Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat (2011) 1.35
Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res (2008) 1.35
Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med (2011) 1.34
CXXC5 is a novel BMP4-regulated modulator of Wnt signaling in neural stem cells. J Biol Chem (2008) 1.23
Mitogen-activated protein kinases promote WNT/beta-catenin signaling via phosphorylation of LRP6. Mol Cell Biol (2010) 1.19
Receptor tyrosine kinases activate canonical WNT/β-catenin signaling via MAP kinase/LRP6 pathway and direct β-catenin phosphorylation. PLoS One (2012) 1.18
Amer1/WTX couples Wnt-induced formation of PtdIns(4,5)P2 to LRP6 phosphorylation. EMBO J (2011) 1.18
FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum Mol Genet (2008) 1.15
Wnt5a regulates ventral midbrain morphogenesis and the development of A9-A10 dopaminergic cells in vivo. PLoS One (2008) 1.14
Wnt5a cooperates with canonical Wnts to generate midbrain dopaminergic neurons in vivo and in stem cells. Proc Natl Acad Sci U S A (2013) 1.12
Marked phenotypic variability in progressive diaphyseal dysplasia (Camurati-Engelmann disease): report of a four-generation pedigree, identification of a mutation in TGFB1, and review. Am J Med Genet A (2004) 1.10
Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. Mol Cell Neurosci (2005) 1.09
Ehlers-Danlos type VIII, periodontitis-type: further delineation of the syndrome in a four-generation pedigree. Am J Med Genet A (2011) 1.08
FGF2 inhibits proliferation and alters the cartilage-like phenotype of RCS cells. Exp Cell Res (2004) 1.05
Sequential activation and inactivation of Dishevelled in the Wnt/beta-catenin pathway by casein kinases. J Biol Chem (2011) 1.04
Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One (2008) 1.02
Vang-like protein 2 and Rac1 interact to regulate adherens junctions. J Cell Sci (2010) 1.02
Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has deficient canonical FGF signaling. Am J Hum Genet (2012) 1.02
Huwe1-mediated ubiquitylation of dishevelled defines a negative feedback loop in the Wnt signaling pathway. Sci Signal (2014) 1.01
C-natriuretic peptide: an important regulator of cartilage. Mol Genet Metab (2007) 1.01
The antiapoptotic protein Api5 and its partner, high molecular weight FGF2, are up-regulated in B cell chronic lymphoid leukemia. J Leukoc Biol (2007) 1.01
Negative regulation of Wnt signaling mediated by CK1-phosphorylated Dishevelled via Ror2. FASEB J (2010) 1.00
Valproic acid induces differentiation and inhibition of proliferation in neural progenitor cells via the beta-catenin-Ras-ERK-p21Cip/WAF1 pathway. BMC Cell Biol (2008) 0.98
STAT1 and STAT3 do not participate in FGF-mediated growth arrest in chondrocytes. J Cell Sci (2008) 0.97
Wnt5a is required for endothelial differentiation of embryonic stem cells and vascularization via pathways involving both Wnt/beta-catenin and protein kinase Calpha. Circ Res (2008) 0.97
Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. J Biol Chem (2006) 0.97
FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. Bone (2010) 0.96
BMPER mutation in diaphanospondylodysostosis identified by ancestral autozygosity mapping and targeted high-throughput sequencing. Am J Hum Genet (2010) 0.94
The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity. Stem Cells (2013) 0.93
Fibrochondrogenesis results from mutations in the COL11A1 type XI collagen gene. Am J Hum Genet (2010) 0.93
SFRP1 and SFRP2 dose-dependently regulate midbrain dopamine neuron development in vivo and in embryonic stem cells. Stem Cells (2012) 0.90
Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis (2006) 0.89
Differentiating campomelic dysplasia from Cumming syndrome. Am J Med Genet A (2005) 0.89
NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J Biol Chem (2010) 0.89
Diaphanospondylodysostosis: six new cases and exclusion of the candidate genes, PAX1 and MEOX1. Am J Med Genet A (2007) 0.89
Osteocraniostenosis-hypomineralized skull with gracile long bones and splenic hypoplasia. Four new cases with distinctive chondro-osseous morphology. Am J Med Genet A (2006) 0.88
Fibroblast growth factors 1, 2, 17, and 19 are the predominant FGF ligands expressed in human fetal growth plate cartilage. Pediatr Res (2007) 0.88
Structural and functional characterization of the Wnt inhibitor APC membrane recruitment 1 (Amer1). J Biol Chem (2011) 0.88
A novel ZRS mutation leads to preaxial polydactyly type 2 in a heterozygous form and Werner mesomelic syndrome in a homozygous form. Hum Mutat (2014) 0.87
Wnt2 regulates progenitor proliferation in the developing ventral midbrain. J Biol Chem (2009) 0.87
More than meets the eye: The evolving phenotype of Weill-Marchesani syndrome-diagnostic confusion with geleophysic dysplasia. Am J Med Genet A (2013) 0.86
Cardiopulmonary exercise testing in Fabry disease. Respiration (2005) 0.86
Fibroblast growth factor inhibits interferon gamma-STAT1 and interleukin 6-STAT3 signaling in chondrocytes. Cell Signal (2008) 0.84
Apoptosis inhibitor 5 (API-5; AAC-11; FIF) is upregulated in human carcinomas in vivo. Oncol Lett (2012) 0.84
Dynamic cervicomedullary cord compression and alterations in cerebrospinal fluid dynamics in children with achondroplasia. Report of four cases. J Neurosurg (2007) 0.84
Disheveled regulates precoupling of heterotrimeric G proteins to Frizzled 6. FASEB J (2014) 0.83
WNT unrelated activities in commercially available preparations of recombinant WNT3a. J Cell Biochem (2010) 0.82
WNT-5A stimulates the GDP/GTP exchange at pertussis toxin-sensitive heterotrimeric G proteins. Cell Signal (2010) 0.82
Fabry disease in a renal allograft. Am J Transplant (2003) 0.81
Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway. Invest New Drugs (2007) 0.80
Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J (2010) 0.80
Mutations in the EVC1 gene are not a common finding in the Ellis-van Creveld and short rib-polydactyly type III syndromes. Am J Med Genet A (2004) 0.80
In vitro proliferation of fibrosarcoma cells depends on intact functions of lipoxygenases and cytochrome P-450-monooxygenase. Cancer Invest (2004) 0.79
Asymmetry of VANGL2 in migrating lymphocytes as a tool to monitor activity of the mammalian WNT/planar cell polarity pathway. Cell Commun Signal (2015) 0.79
A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells. Hum Mol Genet (2009) 0.78
Regulation of the metabolism of polyunsaturated Fatty acids and butyrate in colon cancer cells. Curr Pharm Biotechnol (2013) 0.77
Instability restricts signaling of multiple fibroblast growth factors. Cell Mol Life Sci (2015) 0.77
The appearance of truncated cyclin A2 correlates with differentiation of mouse embryonic stem cells. Biochem Biophys Res Commun (2003) 0.76
Prenatal cortical hyperostosis (Caffey disease). Pediatr Radiol (2002) 0.75
MAC'09, Otto and us…. Mitochondrion (2010) 0.75
Expression of FGF19 in human embryonic stem cells. Stem Cells (2013) 0.75
Multidrug resistance-associated ABC transporters - too much of one thing, good for nothing. Biomol Concepts (2012) 0.75
Clinical and laboratory features of leukemias at the time of diagnosis: an analysis of 1,004 consecutive patients. Am J Hematol (2011) 0.75
Spondylo-mega-epiphyseal dysplasia with prominent upper limb mesomelia, punctate calcifications, and deafness. Am J Med Genet A (2005) 0.75
Cerebro-osseous-digital syndrome: four new cases of a lethal skeletal dysplasia--distinct from Neu-Laxova Syndrome. Am J Med Genet (2002) 0.75
Lysosomal Disease Network's "WORLD Symposium 2009". Introduction. Mol Genet Metab (2008) 0.75
Orthopaedic manifestations of Marinesco-Sjögren syndrome. J Pediatr Orthop (2002) 0.75